HIV Diagnosis Market to Hit USD 5.31 Billion by 2030 with 10.3% CAGR
"The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany)"
Browse 332 market data Tables and 50 Figures spread through 273 Pages and in-depth TOC on "HIV Diagnostics Market by Product (Assay Kits & Reagents, Instrument, Software), Test Type (Rapid Test, ELISA, Western Blot, Viral Load, CD4 Test), End User (Diagnostic Laboratories, Homecare Settings, Hospital) - Global Forecast to 2030
The global HIV diagnosis market, valued at US$2.96 billion in 2024, is forecasted to grow at a robust CAGR of 10.3%, reaching US$3.25 billion in 2025 and an impressive US$5.31 billion by 2030. The HIV diagnostics market is driven by several key factors, such as the rising prevalence of HIV/AIDS, the increasing number of blood transfusions and blood donations, advantages offered by POC diagnostic kits & instruments, and the growing focus on initiatives for HIV awareness. However, the high cost of nucleic acid testing, operational barriers, and the shortage of skilled laboratory technicians are expected to restrain the market growth to a certain extent.
Efforts driven by government health initiatives and public awareness campaigns promoting HIV testing are significantly boosting market growth. Additionally, innovations in testing technologies, such as rapid tests and self-testing kits, along with improved accuracy and ease of use, are enhancing patient compliance and encouraging wider adoption. Despite these positive developments, challenges like the high cost of diagnostic tests and complex testing procedures may slow down growth. However, the market is expected to continue progressing steadily, fueled by a stronger emphasis on early detection, improved healthcare access, and the increasing availability of advanced, convenient testing solutions.
Browse in-depth TOC on " HIV Diagnosis Market"
332 - Tables
50 - Figures
273 - Pages
Based on product type, the HIV diagnostics market is divided into consumables, instruments and software& services. In 2024, the consumables segment accounted for the largest share of the HIV diagnostics market. The large share and the high growth rate of the consumables segment can be attributed to the frequent & repetitive purchase of consumables by laboratories and hospitals; the growing prevalence of HIV/AIDS; and favorable government initiatives to launch advanced consumables in the market.
Based on Test Type, the HIV diagnostics market is segmented into screening tests, confirmatory tests and monitoring tests. The monitoring tests segment accounted for the largest share of the HIV diagnostics market in 2024. This segment is also expected to grow at the highest CAGR owing to the increasing awareness of HIV testing; the high volume of monitoring test samples; and the growing establishment of diagnostic laboratories for testing of HIV/AIDS. Additional factors include technological advancements in monitoring testing kits.
Based on end users, the HIV diagnostics market is segmented into diagnostic laboratories, hospitals, blood banks, home cares settings and other end users. The diagnostic laboratories segment accounted for the largest share of the HIV diagnostics market in 2024. The large share of this segment owed to the increasing prevalence of HIV/AIDS; the rising establishment of diagnostic laboratories; growing sample testing; and advancements in PoC instruments.
The HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominates the global market and is expected to continue during the forecast period. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North America.
However, the Asia Pacific market is expected to grow at the highest CAGR of 12.5% during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this region.
The major market players involved in this market are Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and Grifols, S.A. (Spain), Bio-Rad Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Hologic, Inc. (US), QIAGEN (Germany), Becton, Dickinson, and Company (US), Trinity Biotech (Ireland), OraSure Technologies (US), BioSynex SA (Chembio Diagnostics) (France), Wondfo (China), Getein Biotech Inc. (China), Meril Diagnostics (India), AccuBioTech (China), BioLytical Laboratories Inc. (Canada), BioLab Diagnostics (India), Alpine Biomedicals Pvt. Ltd (India), Molbio Diagnostics (India), Fortress Diagnostics (UK), AdvaCare Pharma (US), Adaltis s.r.l (Italy) among others.
ABBOTT (US)
Abbott is the leading player in the HIV diagnostics market. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets. The company has a strong product portfolio, and its FDA- and CE-approved products have helped it gain a sizable market share. Abbott focuses on inorganic growth strategies, such as collaborations and acquisitions, to enhance its product portfolio and expand its geographical presence. The company's extensive research & development activities for product development and its ongoing clinical trials for newly developed products will further enhance its share in the HIV diagnostics market.
SIEMENS HEALTHINEERS AG (GERMANY)
Siemens Healthineers AG is among the leading players in the global HIV diagnostics market. The company provides a comprehensive portfolio of medical solutions, from medical imaging and in vitro diagnostics to interventional and clinical information technology systems. The company focuses on organic strategies, including product approvals, to enhance its presence in the global POC market. It also aims to create innovative products that address the unmet needs of patients and healthcare providers and take the first-mover advantage. The company also focuses on partnerships and collaborations to enhance its market presence. For instance, in December 2023, Siemens Healthineers AG and OU Health entered a 10-year value partnership to bring the latest diagnostic and therapeutic equipment to people across Oklahoma.
THERMO FISHER SCIENTIFIC (US)
Thermo Fisher Scientific is a key player in the global HIV diagnostics market, offering a comprehensive range of diagnostic solutions, including PCR-based assays, immunoassays, and molecular testing technologies. The company has a strong presence in developed and emerging markets, leveraging its advanced research capabilities and extensive distribution network. Thermo Fisher focuses on continuous innovation, regulatory approvals, and strategic acquisitions to expand its product portfolio. Additionally, the company collaborates with healthcare organizations and government agencies to enhance diagnostic accessibility and improve early detection of HIV.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
5 hours ago
- CTV News
Sask. researchers testing milk kefir for potential Alzheimer's treatment
Watch Saskatchewan researchers are testing compounds of milk kefir in hopes to develop a treatment for Alzheimer's. Allison Bamford reports.
CTV News
5 hours ago
- CTV News
CTV National News: Canadians turn to AI for medical diagnoses
Watch As many Canadians don't have family doctors, some are turning to AI however the technology can be inaccurate at times. John Vennavally-Rao reports.
CTV News
6 hours ago
- CTV News
Researchers urge caution when using ChatGPT to self-diagnose illnesses
Researchers examined the use of ChatGPT-4 to self-diagnose health problems. As Canadians increasingly turn to artificial intelligence for quick answers about health problems, a new study warns relying on tools like ChatGPT for self-diagnosis could be risky. A team, led by researchers at the University of Waterloo, evaluated the performance of ChatGPT-4, a large language model (LLM) released by OpenAI. The chatbot was asked a series of open-ended medical questions based on scenarios modified from a medical licensing exam. The findings were striking. Only 31 per cent of ChatGPT's responses were deemed entirely correct, and just 34 per cent were considered clear. Troy Zada Sirisha Rambhatla PhD student Troy Zada and Dr. Sirisha Rambhatla at the University of Waterloo are part of the research team. 'So, not that high,' said Troy Zada, a PhD student at the University of Waterloo who led the research team. 'If it is telling you that this is the right answer, even though it's wrong, that's a big problem, right?'' The researchers compared ChatGPT-4 with its earlier 3.5 version and found significant improvements, but not enough. In one example, the chatbot confidently diagnosed a patient's rash as a reaction to laundry detergent. In reality, it was caused by latex gloves — a key detail missed by the AI, which had been told the patient studied mortuary science and used gloves. The researchers concluded that LLMs are not yet reliable enough to replace medical professionals and should be used with caution when it comes to health matters. This is despite studies that have found AI chatbots can best human doctors in certain situations and pass medical exams involving multiple choice questions. Zada said he's not suggesting people stop using ChatGPT for medical information, but they must be aware of its limitations and potential for misinformation. 'It could tell you everything is fine when there's actually a serious underlying issue,' said Zada. He says it could also offer up information that would make someone needlessly worry. Millions of Canadians currently do not have a family doctor and there are concerns some may be relying on artificial intelligence to diagnose health problems, even though AI chatbots often advise users to consult an actual doctor. The researchers also noted the chatbots lack accountability, whereas a human doctor can face severe consequences for errors, such as having their licence revoked or being charged with medical malpractice. While the researchers note ChatGPT did not get any of the answers spectacularly wrong, they have some simple advice. 'When you do get a response be sure to validate that response,' said Zada. Dr. Amrit Kirpalani agrees. He's a pediatric nephrologist and assistant professor at Western University who has studied AI in medicine and has noticed more patients and their family members bringing up AI platforms such as ChatGPT. He believes doctors should initiate conversations about its use with patients because some may be hesitant to talk about it. 'Nobody wants to tell their doctor that they went on ChatGPT and it told them something different,' says Kirpalani. He'd prefer patients discuss a chatbot's response with a physician, especially since an AI can sometimes be even more persuasive than a human. 'I'm not sure I could be as convincing as an AI tool. They can explain some things in a much more simple and understandable way,' says Kirpalani. 'But the accuracy isn't always there. So it could be so convincing even when it's wrong.' He likens AI to another familiar online tool. 'I kind of use the Wikipedia analogy of, it can be a great source of information, but it shouldn't be your primary source. It can be a jumping-off point.' The researchers also acknowledge as LLMs continue to improve, they could eventually be reliably used in a medical setting. But for now, Zada has this to say: 'Don't blindly accept the results.'
